Chondroitin and glucosamine offer minimal knee pain relief

Clara Nilsen, Endurance planning editor (AI-assisted) ·

Most people who reach for chondroitin or glucosamine for knee pain believe the supplements are proven remedies. But the largest placebo-controlled trials and systematic reviews in adults with knee osteoarthritis show differences from placebo that fall short of what doctors consider a meaningful effect, with every major study enrolling only older adults with established joint disease—not healthy runners or those with overuse pain. Here is what the evidence says, point by point.

Placebo-controlled trials show no significant pain difference in most adults with knee osteoarthritis

The largest and most cited trial, the GAIT study, randomly assigned 1,583 adults with symptomatic knee osteoarthritis to daily glucosamine, chondroitin, both, celecoxib (an NSAID), or placebo for 24 weeks [1]. The response rate for pain improvement in the placebo group was already high at 60.1% [1]. Chondroitin alone gave a 5.3 percentage point higher response than placebo (not statistically significant), and the combination with glucosamine was 6.5 points higher (also not significant) [1]. In contrast, celecoxib produced a 10 percentage point higher response (statistically significant, P=0.008) [1].

The GAIT trial also examined people with moderate-to-severe pain at the start. In this smaller subgroup, the response to the chondroitin-glucosamine combination was 79.2% versus 54.3% for placebo—a significant difference (P=0.002) [1]. But for the majority with milder pain, there was no evidence of benefit beyond placebo.

A two-year trial, the LEGS study, followed 605 adults with chronic knee pain and radiographic joint narrowing [1]. All groups—glucosamine, chondroitin, the combination, and placebo—reported reduced knee pain over the first year, with no significant differences between groups (p=0.93) [1]. The combination did reduce joint space narrowing by 0.10 mm more than placebo over two years, but this structural change was small and its clinical impact is uncertain [1].

Meta-analyses and reviews find pain improvements are below the threshold for clinical importance

Pooled reviews and large trials in older adults with knee osteoarthritis find chondroitin and glucosamine deliver only small pain reductions against placebo, well short of most thresholds for a meaningful clinical effect. Our own aggregation (site owner's data, 15 November 2026) finds the 2010 network meta-analysis of 3,803 patients reported pain fell by -0.3 cm (chondroitin) and -0.5 cm (combination) on a 10 cm visual analogue scale, compared to a -0.9 cm difference that the analysis prespecified as clinically important [1]. Trials funded independently of supplement manufacturers showed even smaller effects (P=0.02 for interaction) [1].

The 2015 Cochrane review, pooling 43 randomized trials with 9,110 participants, found chondroitin users rated their pain 10 points lower than placebo on a 0-100 scale in studies under six months (absolute pain: 18 vs 28), but the evidence was rated low quality and the improvement did not meet commonly accepted thresholds for clinical benefit [1]. Out of 100 people taking chondroitin, 53 had a 20% pain improvement, versus 47 on placebo—a 6% absolute difference [1].

A summary from our review of the source data [1]:

Study/ReviewPain difference vs placeboPain scale usedNumber of participants
GAIT (chondroitin)+5.3 percentage points% with 20% pain improvement1583
GAIT (combination)+6.5 percentage points% with 20% pain improvement1583
BMJ meta-analysis-0.3 cm (chondroitin)10 cm visual analogue scale3803
BMJ meta-analysis-0.5 cm (combination)10 cm visual analogue scale3803
Cochrane review-10 points (chondroitin)0-100 pain scale9110
Cochrane review53/100 (chondroitin), 47/100 (placebo)% with 20% pain improvement9110

In practical terms, the pain reductions seen in these reviews are small and no trial in the data enrolled healthy runners or people with knee pain but no osteoarthritis [1]. If your aim is to relieve non-arthritic knee pain from running, these figures do not support relying on chondroitin or glucosamine as a primary intervention.

Some trials found structural joint changes, but pain outcomes did not differ from placebo

A few trials reported small differences in joint structure, but these did not translate into pain relief. In the LEGS trial, the chondroitin-glucosamine combination slowed joint space narrowing by 0.10 mm over two years compared to placebo (p=0.046), yet there was no significant difference in knee pain between groups at any time point [1]. No pooled review or large trial in our analysis found a consistent pain benefit alongside these structural changes, and none measured a clinically relevant improvement for function or symptoms in everyday activity [1].

One outlier, the CONCEPT trial of pharmaceutical-grade chondroitin sulfate in 604 older adults with knee osteoarthritis, found pain fell by 42.6 mm on a 100 mm scale with chondroitin versus 33.3 mm with placebo—a difference of 9.3 mm (p=0.001) [1]. This matches the Cochrane review’s pooled short-term benefit of 10 points, but remains below the minimum threshold most guidelines require for clinical importance [1].

All trials enrolled older adults with knee osteoarthritis—not healthy runners

None of the large trials or pooled analyses enrolled healthy runners, endurance athletes, or people with knee pain unrelated to osteoarthritis [1]. The typical participant was an adult aged 45 or older with diagnosed knee osteoarthritis, often confirmed on X-ray [1]. No evidence from these studies addresses whether chondroitin or glucosamine prevent knee pain from running, treat runner’s knee (patellofemoral pain), or help in non-arthritic joint aches.

The supplement’s popularity among athletes and active adults comes from its over-the-counter status and the assumption that it “supports joint health.” But the clinical trial evidence covers only older adults with chronic, structural knee disease.

What this does not show

Because every major trial and review focused on people with established knee osteoarthritis, you cannot apply their results to healthy athletes, runners with overuse injuries, or prevention of cartilage damage from high mileage [1]. The evidence does not show benefit—or harm—for these groups, because no trials studied them.

National guidelines reflect this limitation: the US National Center for Complementary and Integrative Health notes “it’s still uncertain whether glucosamine and chondroitin are helpful for knee osteoarthritis symptoms,” and the 2019 American College of Rheumatology guideline strongly recommends against using either for knee osteoarthritis [1].

Questions readers ask

Can chondroitin or glucosamine prevent knee problems if I run a lot?

There are no trials studying healthy runners or athletes without osteoarthritis, so there is no evidence these supplements prevent knee pain or cartilage damage from running [1].

Do any patients with knee osteoarthritis benefit more than average?

An exploratory analysis in the GAIT trial found that people with moderate-to-severe pain at baseline saw a higher response rate with the combination supplement (79.2% vs. 54.3% for placebo, P=0.002) [1]. This result is not considered definitive and applies only to this small subgroup.

Are there risks to taking chondroitin or glucosamine?

In the major trials and reviews, rates of adverse events were similar to placebo, and no major safety concerns were found over periods up to three years [1]. However, supplements should not replace other proven therapies, and some guidelines recommend against their use for osteoarthritis.

---

If you have knee pain from osteoarthritis and are considering chondroitin or glucosamine, the main trials show pain improvements no greater than 10 points out of 100 over placebo, a difference that falls below accepted thresholds for clinical benefit—while no evidence addresses use in healthy, active adults or runners [1].

How the numbers work

Computed from the numbered sources and the assumptions named below; change an assumption and the results change with it.

FigureValueWhere it comes from
Placebo response rate (GAIT trial)60.1 %source [1]
Pain improvement vs placebo (CONCEPT trial)9.3 mmsource [1]
Short-term pain improvement vs placebo (Cochrane review)10 pointssource [1]
Chondroitin 20% pain improvement rate (Cochrane review)53 %source [1]
Placebo 20% pain improvement rate (Cochrane review)47 %source [1]
Pain difference vs placebo (chondroitin, BMJ meta-analysis)-0.3 cmsource [1]
Minimal clinically important difference (BMJ meta-analysis)-0.9 cmsource [1]
Difference in 20% responders: Chondroitin minus placebo (Cochrane)6 %computed: Chondroitin 20% pain improvement rate (Cochrane review) - Placebo 20% pain improvement rate (Cochrane review)
Chondroitin effect vs minimal clinically important difference (BMJ)33 %computed: abs(Pain difference vs placebo (chondroitin, BMJ meta-analysis)) ÷ abs(Minimal clinically important difference (BMJ meta-analysis)) × 100
CONCEPT trial pain difference as % of Cochrane93 %computed: Pain improvement vs placebo (CONCEPT trial) ÷ Short-term pain improvement vs placebo (Cochrane review) × 100
Value (%)
Difference in 20% responders: Chondroitin minus placebo (Cochrane)6
Chondroitin effect vs minimal clinically important difference (BMJ)33
CONCEPT trial pain difference as % of Cochrane93

Computed from the figures in the table above.

Sources

  1. Our own data, 15 Nov 2026: Chondroitin and glucosamine for knee pain: the trials and reviews, figure by figure

More articles